⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NeuroSense Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NeuroSense Therapeutics
↗Herzliya, Israel
NeuroSense Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of targeted innovative therapeutics for debilitating neurodegenerative diseases, including ALS, Parkinson's, and Alzheimer's disease. The company aims to address unmet medical needs by creating combined therapeutic strategies that target multiple pertinent mechanisms in these complex diseases.
Founded in 2017 and headquartered in Herzliya, Israel, with a presence in Cambridge, MA, the company's lead product candidate, PrimeC, is an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib. PrimeC has received orphan drug designation from the FDA and EMA for the treatment of ALS and has demonstrated promising results in Phase 2b clinical trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$24.2M
STOCK
Exchange:NASDAQ
Ticker:NRSN
Market Cap:$0.02B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 2b/3
Modalities:Small molecule
Active Trials:2
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Alon Ben-Noon - Co-Founder, CEO & Director
Mark Wayne Leuchtenberger - Independent Chairman of the Board
LINKS
Website:neurosense-tx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NeuroSense Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.